nursing-forum-rheumatology-2019-keynote

3 / 7

Page 14
September 02-03, 2019 | Vienna, Austria
Volume 3 | ISSSN: 2632-251X Nursing Forum 2019 & Rheumatology 2019
September 02-03, 2019
Journal name: Journal of Nursing Research and Practice
WORLD NURSING FORUM
RHEUMATOLOGY & TRAUMA CARE
13th International Conference on
&
J Nurs Res Pract, Volume 3
Cytorich: A novel anti-inflammatory/catabolic and regenerative autologous blood-
derived product for osteoarthritis treatment
Statement of the Problem: Osteoarthritis (OA) is degenerative joint disease characterized by cartilage damage and
synovial inflammation. Autologous blood-derived products target special inflammatory molecular pathways and have a
beneficial therapeutic effect for inflammatory pathologies. The purpose of this study was to assess the in vitro and in vivo
anti-inflammatory/ catabolic and regenerative potential of a novel autologous blood product (Cytorich).
Materials and Methods: Blood samples from healthy donors were incubated using different techniques for 24h and
analyzed for the presence of anti-inflammatory (IL-1ra), anti-catabolic (tissue inhibitors of metalloproteinases, TIMPs),
regenerative, pro-inflammatory (TNF-?, IL-1) and catabolic (matrix metalloproteinases, MMPs) molecules. Double-
blinded controlled clinical study was conducted to evaluate clinical effectiveness and safety of the final product using
VAS (Visual Analog Scale) and WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scales.
Results: The highest concentration of therapeutic molecules targeting inflammatory and degeneration pathways in OA,
as well as platelet-derived growth factor, was found in 24h 37°C incubated blood. However, the increased production of
catabolic MMP9 and TNF-? and IL-1 was detected in the product. We have found that this negative effect could be blocked
by adding citric acid making future OA treatment safer and more effective. Double-blinded controlled clinical study has
shown a safety and efficiency of this new product. The analysis of WOMAC and VAS scores revealed improvement in
pain and daily activities parameters.
Conclusion and Significance: Cytorich is an efficient and safe autologous product for OA treatment since it has been
reported as a source of human bioactive molecules playing a key role in the fundamental processes stimulating tissue
repair and regeneration.
Biography
Anthony Galea practices sport medicine in Toronto and is considered one of the pioneers in the uses and applications of platelet rich plasma
in musculoskeletal disorders. He has functioned as a sport physician for many professional and Olympic competitions and his clients includes
some of the world’s best athletes. He is also an author and researcher; his current research focuses on autologous cytokines for the treatment
of osteoarthritis. He is married with seven children.
Anthony Galea
Galea Professional Medical Inc., Canada